Effect of calcium channel or β-blockade on the progression of diabetic nephropathy in African Americans

Hypertension

Volumn 29, Issue 3, 1997, Pages 744-750

  Bakris, George L ^a,b   Mangrum, Amy ^b   Copley, J Brian ^a   Vicknair, Nancy ^a   Sadler, Rebecca ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

adrenergic beta antagonists; atenolol; blacks; calcium channel blockers; diabetic nephropathies; verapamil

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; VERAPAMIL;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG EFFECT; ETHNIC GROUP; FATIGUE; FEMALE; HUMAN; HYPERTENSION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NEGRO; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SUSTAINED RELEASE PREPARATION; TREATMENT OUTCOME;

EID: 0031020448     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.29.3.744     Document Type: Article

References (35)

1. Brancati FL, Whittle JC, Welton PK. The excess incidence of diabetic end-stage renal disease among blacks. JAMA. 1992;268:3079-3084.
2. Geiss LS, Herman WH, Goldschmid MG, DeStefano F, Eberhardt F, Eberhardt MS. Surveillance for diabetes mellitus: United States, 1980-1989. MMWR Morb Mortal Wkly Rep. 1993;42:1-20.
3. Parving HH. The impact of hypertension and antihypertensive treatment on the course and prognosis of diabetic nephropathy. J Hypertens. 1990;8:S187-S191.
4. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King A, Klahr S, Massry SG, Seifter JL. Blood pressure control, proteinuria and the progression of renal disease: the Modification of Diet in Renal Disease Study. Ann Intern Med. 1995;123:754-762.
5. Toto RD, Mitchell NC, Smith RD. 'Strict' blood pressure control and progression of renal disease in hypertensive nephrosclerosis. Kidney Int. 1995;48:851-859.
6. Zing W, Ferguson RK, Vlasses PN. Calcium antagonists in elderly and black hypertensive patients. Arch Intern Med. 1991;151: 2154-2162.
7. Walker WG, Hermann JA, Anderson JE. Randomized doubly blinded trial of enalapril vs hydrochlorothiazide on glomerular filtration rate in diabetic nephropathy. Hypertension. 1993;22:410. Abstract.
8. Saunders E, Weir MR, Kong BW. A comparison of the efficacy and safety of a beta blocker, calcium channel blocker and converting enzyme inhibitor in hypertensive blacks. Arch Intern Med. 1990; 150:1707-1713.
9. Brazy PC, Fitzwilliam JF. Progression of renal insufficiency: role of blood pressure. Kidney Int. 1989;35:670-674.
10. Luft FC, Miller JZ, Grim CE. Salt sensitivity and resistance of blood pressure, age and race as factors in physiological responses. Hypertension. 1991;17(suppl I):I-102-I-108.
11. Bakris GL, Weir MR. Salt intake and reductions in arterial pressure and proteinuria: is there a direct link? Am J Hypertens. 1996;9: 200S-206S.
12. Bakris GL. Microalbuminuria: prognostic implications. Curr Opin Nephrol Hypertens. 1996;5:219-223.
13. Lash JP, Bakris GL. Effects of ACE inhibitors and calcium antagonists alone or combined on progression of diabetic nephropathy. Nephrol Dial Transplant. 1995;10(suppl 9):56-62.
14. Gansevoort RT, Sluiter WJ, Hemmelder MH, de Zeeuw D, de Jong PE. Antiproteinuric effect of blood pressure lowering agents: a meta-analysis of comparative trials. Nephrol Dial Transplant. 1995;10: 1963-1974.
15. Maki DD, Ma JZ, Louis TA, Kasiske BL. Long-term effects of anti-hypertensive agents on proteinuria and renal function. Arch Intern Med. 1995;155:1073-1080.
16. Weidmann P, Schneider M, Bohlen L. Therapeutic efficacy of different anti-hypertensive drugs in human diabetic nephropathy: an updated meta-analysis. Nephrol Dial Transplant. 1995;10(suppl 9):39-45.
17. Bakris GL, Smith AC. Effects of sodium intake on albumin excretion in patients with diabetic nephropathy treated with long-acting calcium antagonists. Ann Intern Med. 1996;125:201-203.
18. Abbott K, Smith AC, Bakris GL. Effects of dihydropyridine calcium antagonists on albuminuria in diabetic subjects. J Clin Pharmacol. 1996;36:274-279.
19. SAS Institute Inc. SAS/STAT User's Guide, Version 6. 4th ed. Cary, NC: SAS Institute Inc; 1989;1:943.
20. Statistical Sciences. S-PLUS User's Manual, Version 3.2. Seattle, Wash: StatSci, division of MathSoft Inc; 1993:1-15.
21. National High Blood Pressure Education Program Working Group on Hypertension and Renal Disease. 1995 Update of the working group reports on chronic renal failure and renovascular hypertension. Arch Intern Med. 1996;156:1938-1947.
22. Slataper R, Vicknair N, Sadler R, Bakris GL. Comparative effects of different antihypertensive treatments on progression of diabetic renal disease. Arch Intern Med. 1993;153:973-980.
23. Bjorck S, Mulec H, Johnsen SA, Nyberg G, Aurell M. Contrasting effects of enalapril and metoprolol on proteinuria in diabetic nephropathy. Br Med J. 1990;300:904-907.
24. Elliott WJ. Compliance strategies. Curr Opin Nephrol Hypertens. 1994;3:271-278.
25. Hebert LA, Bain RP, Verme D, Cattran D, Whittier FC, Tolchin N, Rohde RD, Lewis EJ, for the Collaborative Study Group. Remission of nephrotic range proteinuria in type I diabetes. Kidney Int. 1994; 46:1688-1693.
26. Bakris GL, Williams B. ACE inhibitors and calcium antagonists alone or combined: is there a difference on progression of diabetic renal disease? J Hypertens. 1995;13(suppl 2):S95-S101.
27. Smith AC, Bakris GL. Differential effects of calcium channel blockers on glomerular permeability in NIDDM patients: results of a two year study. J Am Soc Nephrol. 1996;7:1364. Abstract.
28. Cohen MP, Sharma K, Jin Y, Hud E, Wu VY, Tomaszewski J, Ziyadeh FN. Prevention of diabetic nephropathy in db/db mice with glycated albumin antagonists: a novel treatment strategy. J Clin Invest. 1995;95:2338-2345.
29. Kesteloot H, Joossens JV. On the determinants of the creatinine clearance: a population study. J Hum Hypertens. 1996;10:245-249.
30. Lemann J, Bidani A, Bain RP, Lewis E, Rohde RD, and the Collaborative Study Group. Use of serum creatinine to estimate glomerular filtration rate in health and early diabetic nephropathy. Am J Kidney Dis. 1990;16:236-243.
31. Toto RD, Kirk KA, Coresh J, Jones C, Appel L, Wright J, Campese V, Olutade B, Agodoa L, and the AASK Pilot Study Investigators. Evaluation of serum creatinine for estimating glomerular filtration rate in blacks with hypertensive nephrosclerosis: results from the African-American Study of Kidney Disease and Hypertension (AASK). J Am Soc Nephrol. In press.
32. Kasinath BS, Mujais SK, Spargo BH, Katz AI. Nondiabetic renal disease in patients with diabetes mellitus. Am J Med. 1983;75: 613-617.
33. John GT, Date A, Korula A, Jeyaseelan L, Shastry C, Jacob CK. Nondiabetic renal disease in noninsulin dependent diabetics in a south Indian hospital. Nephron. 1994;67:441-443.
34. Bakris GL, Weir MR, DeQuattro V, Rosendorff C, MacMahon G. Renal hemo-dynamic and antiproteinuric response to an ACE inhibitor, trandolopril, or calcium antagonist, verapamil, alone or in fixed dose combination in patients with diabetic nephropathy: a randomized multicentered study. J Am Soc Nephrol. 1996;7:1546. Abstract.
35. Bakris GL. Combination therapy for Hypertension and renal disease in diabetes. In: Mogensen CE, ed. The Kidney and Hypertension in Diabetes Mellitus. 3rd ed. Boston, Mass: Kluwer Academic Press; 1997:561-568.